Pembrolizumab, commercially known as “Keytruda”, is a humanized IgG4 Kappa monoclonal antibody targeted against PD-1 on T cells present in tumors, blocking their interaction with PD-L1 on tumor cells. The gene discussed is PDCD1; the disease is neoplasm.